From:  Mechanisms and kinetics of drug release from lignin-based hydrogels: a review

 Summary of lignin-based hydrogels for drug delivery: in vitro release kinetics and in vivo efficacy, highlighting translational challenges and future standardization needs.

AspectIn vitro studiesIn vivo/clinical studiesChallenges & future directionsReferences
Drug release profiles- Lignin-poly(lactic-co-glycolic acid) (PLGA) nanoparticles: controlled florfenicol release via Fickian diffusion; inhibited bacterial biofilms.
- Carboxylated lignocellulose nanofibril-polyvinyl alcohol (CLCNF-PVA) hydrogels: 80.73% release over 36 h, Fickian kinetics.
- Lignin-chitosan: pH-responsive release, high swelling rates.
- Fickian diffusion for coumarin 6 (59% encapsulation) and doxorubicin (DOX) (73% via nanoprecipitation); tumor inhibition, reduced chemotherapy toxicity.
- Hydrogels: Controlled release, biocompatibility.
Limited in vivo validation; standardize models and mathematical tools (e.g., zero-order/Higuchi kinetics) for release characterization.[89, 9395]
Biocompatibility & efficacy- Reduced cytotoxicity, enhanced antimicrobial activity.
- Excellent biocompatibility via cytotoxicity assays.
- Wound healing accelerated to 13 days.
High biocompatibility; promising targeted therapy trials.Sparse in vivo data, no large-scale trials; restricted to lab-scale. Advanced detection (e.g., HPLC-MS) for safety/efficacy.[9597]
Applications & potentialSustainable biopolymer for sustained delivery, tissue engineering.Oncology targeting, side-effect mitigation; viable for medicine/engineering.Translational gaps: scale to GMP production, multi-model in vivo studies, Phase I trials.[25, 65, 89, 98100]